Drug Profile
Research programme: peptide therapeutics - Ironwood Pharmaceuticals/Protagonist Therapeutics
Alternative Names: Interleukin 6 peptide antagonistsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ironwood Pharmaceuticals; Protagonist Therapeutics
- Class Peptides
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases